Search Results

BioCorRx Inc. today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.

BioCorRx Inc. today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO).

BioCorRx Inc. announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2023, and reported on recent corporate developments.

BioCorRx Inc. today provided a business update for the three months ended March 31, 2023 and reported on recent corporate developments.

BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, provided a business update for the year ended December 31, 2022 and reported on recent corporate developments.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx, and Brady Granier, President and Director of BioCorRx, will be presenting virtually at the Sequire Biotechnology Conference.

BioCorRx Inc. today announced the submission of a fast track application to the U.S. Food and Drug Administration (“FDA”) for BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD).